IL231448A0 - Phosphatidylinositol 3-kinase inhibitors for cancer treatment - Google Patents

Phosphatidylinositol 3-kinase inhibitors for cancer treatment

Info

Publication number
IL231448A0
IL231448A0 IL231448A IL23144814A IL231448A0 IL 231448 A0 IL231448 A0 IL 231448A0 IL 231448 A IL231448 A IL 231448A IL 23144814 A IL23144814 A IL 23144814A IL 231448 A0 IL231448 A0 IL 231448A0
Authority
IL
Israel
Prior art keywords
phosphatidylinositol
cancer
treatment
kinase inhibitors
kinase
Prior art date
Application number
IL231448A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Sa
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Exelixis Inc filed Critical Sanofi Sa
Publication of IL231448A0 publication Critical patent/IL231448A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL231448A 2011-09-14 2014-03-11 Phosphatidylinositol 3-kinase inhibitors for cancer treatment IL231448A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US201161562670P 2011-11-22 2011-11-22
PCT/US2012/055387 WO2013040337A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL231448A0 true IL231448A0 (en) 2014-04-30

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231448A IL231448A0 (en) 2011-09-14 2014-03-11 Phosphatidylinositol 3-kinase inhibitors for cancer treatment

Country Status (10)

Country Link
EP (1) EP2755654A1 (pt)
KR (1) KR20140077911A (pt)
AU (1) AU2012308414A1 (pt)
BR (1) BR112014005858A2 (pt)
CA (1) CA2848724A1 (pt)
IL (1) IL231448A0 (pt)
IN (1) IN2014CN02671A (pt)
TW (1) TW201325592A (pt)
UY (1) UY34339A (pt)
WO (1) WO2013040337A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
EA024305B1 (ru) * 2005-10-07 2016-09-30 Экселиксис, Инк. Ингибиторы фосфатидилинозит-3-киназы и их применение
KR20140105621A (ko) 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
RS53020B (en) * 2007-04-11 2014-04-30 Exelixis Inc. COMBINED THERAPY CONTAINING HINOXALINE PI3K-ALPHA INHIBITOR FOR USE IN CANCER TREATMENT
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
UY34339A (es) 2013-04-30
KR20140077911A (ko) 2014-06-24
IN2014CN02671A (pt) 2015-07-03
WO2013040337A1 (en) 2013-03-21
AU2012308414A1 (en) 2014-05-01
BR112014005858A2 (pt) 2017-06-13
WO2013040337A9 (en) 2014-04-03
CA2848724A1 (en) 2013-03-21
TW201325592A (zh) 2013-07-01
EP2755654A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
HK1243919A1 (zh) 利用tor激酶抑制劑治療癌症
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
HK1210174A1 (en) Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1193823A1 (zh) 用於治療癌症的作為 -激酶抑制劑的苯並吡喃酮化合物
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
SG10201502566SA (en) Use of novel pan-cdk inhibitors for treating tumors
HK1205500A1 (en) Kinase inhibitors for the treatment of cancer
EP2897607A4 (en) BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
IL231448A0 (en) Phosphatidylinositol 3-kinase inhibitors for cancer treatment
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
HK1202118A1 (en) Piperazinyl derivatives for the treatment of cancer